Biotest Aktiengesellschaft (FRA:BIO)
Market Cap | 1.40B |
Revenue (ttm) | 635.20M |
Net Income (ttm) | -24.50M |
Shares Out | n/a |
EPS (ttm) | -0.63 |
PE Ratio | n/a |
Forward PE | 23.49 |
Dividend | 0.04 (0.09%) |
Ex-Dividend Date | Jul 3, 2025 |
Volume | n/a |
Average Volume | 454 |
Open | 42.20 |
Previous Close | 42.60 |
Day's Range | 42.20 - 42.20 |
52-Week Range | 40.40 - 43.20 |
Beta | n/a |
RSI | 48.94 |
Earnings Date | May 12, 2025 |
About FRA:BIO
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company’s produ... [Read more]
Financial Performance
In 2024, FRA:BIO's revenue was 726.20 million, an increase of 6.08% compared to the previous year's 684.60 million. Earnings were 26.40 million, a decrease of -79.21%.
Financial StatementsNews

EQS-Adhoc: Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG
EQS-Ad-hoc: Biotest AG / Key word(s): Personnel Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG 28-May-2025 / 17:00 CET/CEST Disclosure of an inside information acc. to Article 1...

Biotest Affirms 2025 Guidance with Confidence
Biotest AG's financial landscape shifts dramatically in Q1 2025, marked by a steep 42.3% sales drop and significant profit losses, driven by reduced technology services for Grifols, S.A. Jetzt den vol...

EQS-News: Biotest confirms Guidance for 2025
EQS-News: Biotest AG / Key word(s): Quarterly / Interim Statement Biotest confirms Guidance for 2025 12.05.2025 / 17:35 CET/CEST The issuer is solely responsible for the content of this announcement. ...

EQS-WpÜG: Tender Offer / Target company: Biotest AG; Bidder: Grifols Biotest Holdings GmbH
EQS-WpÜG: Grifols Biotest Holdings GmbH / Tender Offer Tender Offer / Target company: Biotest AG; Bidder: Grifols Biotest Holdings GmbH 31.03.2025 / 08:43 CET/CEST Dissemination of an announcement acc...

EQS-Adhoc: Biotest AG: Delisting agreement and announced delisting tender offer
EQS-Ad-hoc: Biotest AG / Key word(s): Delisting Biotest AG: Delisting agreement and announced delisting tender offer 31-March-2025 / 08:40 CET/CEST Disclosure of an inside information acc. to Article ...

Biotest AG Boosts Sales by 6% in 2024
Biotest AG's financial journey in 2024 paints a picture of both triumph and challenge. With a notable 6.1% sales increase, the company reached new heights at €726.2 million. While EBIT hit the forecas...

EQS-News: Biotest AG increases sales by 6% in financial year 2024
EQS-News: Biotest AG / Key word(s): Annual Report Biotest AG increases sales by 6% in financial year 2024 31.03.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcem...

EQS-Adhoc: Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.
EQS-Ad-hoc: Biotest AG / Key word(s): Personnel Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future. 06-March-2025 / 0...